Trial Profile
A phase I open-label study to evaluate the safety of PROSTVAC-VF/TRICOM [prostate cancer vaccine] in the treatment of subjects with adenocarcinoma of the prostate
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Sep 2012
Price :
$35
*
At a glance
- Drugs Rilimogene galvacirepvec (Primary) ; Rilimogene glafolivec (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Jan 2006 New trial record.